Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 29425
Paxil CRâ„¢ is a modified release version of Paxil/Seroxat (paroxetine HCL) which uses a combination of the Positioned Release and Zero Order Geomatrixâ„¢ systems. Paxil is an FDA-approved drug that is currently marketed primarily in the United States and Europe and is an immediate release formulation prescribed for central nervous system disorders.
IPSCIO Record ID: 27477
Paxil CR is a modified release version of Paxil/Seroxat (paroxetine) using a combination of the Positioned Release and Zero Order Geomatrix systems. Paxil is an FDA-approved (February 1999) drug that is currently marketed primarily in the United States and Europe. In early 2001 an approvable letter from the FDA was received for a second CR indication, panic disorder. A third CR indication, pre-menstrual dysphoric disorder, a severe form of pre-menstrual syndrome is being developed. In April, 2002, the product was launched in the U.S. Note that in May 2005, they renegotiated this license and the upper range of the royalty payment was increased.
IPSCIO Record ID: 29294
IPSCIO Record ID: 26466
IPSCIO Record ID: 27061
The TIMERx drug delivery system is a hydrophilic matrix combining primarily a heterodispersed mixture, usually polysaccharides xanthan and locust bean gums, in the presence of dextrose. The physical interaction between these components works to form a strong, binding gel in the presence of water. Drug release is controlled by the rate of water penetration from the gastrointestinal tract into the TIMERx gum matrix, which expands to form a gel and subsequently releases the active drug substance. The TIMERx system can precisely control the release of the active drug substance in a tablet by varying the proportion of the gums, together with the third component, the tablet coating and the tablet manufacturing process. Drugs using TIMERx technology are formulated by combining the active drug substance, the TIMERx drug delivery system and additional excipients and compressing such materials into a tablet.
1) Directly compressible sustained release excipient.
2) Sustained release excipient and tablet formulation.
3) Compressible sustained release solid dosage forms.
4) EPO Application No. 89309518.2; filed September 19, 1989.
5) Australian Patent Application No. 43057/89
6) Japanese Patent Application No. 1-510135
7) Irish Patent Application No. 2968/89
8) Canadian Patent Application No. 611,700
9) Verapamil Tablet Application, Serial No. 736,031 & EPO PCT Applications.
10) 2 U.S. Applications on Bi-modal release.
IPSCIO Record ID: 336386
GeomatrixÂ® Technology shall mean Licensors proprietary oral, modified release (i.e., controlled-release, sustained-release, or delayed release) drug delivery and related technology which utilizes a hydrophilic drug-containing matrix tablet which controls the release of the drug through the use of one or more barrier layers, together with all improvements thereon or thereto.
Product shall mean shall mean an oral delivery system for Paroxetine based on or using the GeomatrixÂ® Technology.
Patents shall mean
4,839,177 – System for the controlled-rate release of active substances
5,422,123 – Tablets with controlled-rate release of active substances
5,476,654 – Process for preparing pharmaceutical compositions having an increased active substance dissolution rate, and the compositions obtained
SPC shall mean a right based upon a patent to exclude others from making, using or selling product, such as a Supplementary Protection Certificate.